These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica. Ratelade J; Smith AJ; Verkman AS Exp Neurol; 2014 May; 255():145-53. PubMed ID: 24636863 [TBL] [Abstract][Full Text] [Related]
9. Marked central nervous system pathology in CD59 knockout rats following passive transfer of Neuromyelitis optica immunoglobulin G. Yao X; Verkman AS Acta Neuropathol Commun; 2017 Feb; 5(1):15. PubMed ID: 28212662 [TBL] [Abstract][Full Text] [Related]
10. Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59. Zhang H; Verkman AS J Autoimmun; 2014 Sep; 53():67-77. PubMed ID: 24698947 [TBL] [Abstract][Full Text] [Related]
11. Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. Zhang H; Verkman AS J Clin Invest; 2013 May; 123(5):2306-16. PubMed ID: 23563310 [TBL] [Abstract][Full Text] [Related]
12. Unique neuromyelitis optica pathology produced in naïve rats by intracerebral administration of NMO-IgG. Asavapanumas N; Ratelade J; Verkman AS Acta Neuropathol; 2014 Apr; 127(4):539-51. PubMed ID: 24190619 [TBL] [Abstract][Full Text] [Related]
13. Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays. Phuan PW; Ratelade J; Rossi A; Tradtrantip L; Verkman AS J Biol Chem; 2012 Apr; 287(17):13829-39. PubMed ID: 22393049 [TBL] [Abstract][Full Text] [Related]
15. Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G. Asavapanumas N; Ratelade J; Papadopoulos MC; Bennett JL; Levin MH; Verkman AS J Neuroinflammation; 2014 Jan; 11():16. PubMed ID: 24468108 [TBL] [Abstract][Full Text] [Related]
16. Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica. Tradtrantip L; Yao X; Su T; Smith AJ; Verkman AS Acta Neuropathol; 2017 Jul; 134(1):35-44. PubMed ID: 28567523 [TBL] [Abstract][Full Text] [Related]
17. Inhibitor(s) of the classical complement pathway in mouse serum limit the utility of mice as experimental models of neuromyelitis optica. Ratelade J; Verkman AS Mol Immunol; 2014 Nov; 62(1):104-13. PubMed ID: 24980869 [TBL] [Abstract][Full Text] [Related]
18. C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica. Phuan PW; Zhang H; Asavapanumas N; Leviten M; Rosenthal A; Tradtrantip L; Verkman AS Acta Neuropathol; 2013 Jun; 125(6):829-40. PubMed ID: 23677375 [TBL] [Abstract][Full Text] [Related]
19. Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica. Tradtrantip L; Felix CM; Spirig R; Morelli AB; Verkman AS Neuropharmacology; 2018 May; 133():345-353. PubMed ID: 29428821 [TBL] [Abstract][Full Text] [Related]
20. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. Mader S; Gredler V; Schanda K; Rostasy K; Dujmovic I; Pfaller K; Lutterotti A; Jarius S; Di Pauli F; Kuenz B; Ehling R; Hegen H; Deisenhammer F; Aboul-Enein F; Storch MK; Koson P; Drulovic J; Kristoferitsch W; Berger T; Reindl M J Neuroinflammation; 2011 Dec; 8():184. PubMed ID: 22204662 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]